Common Drug Alcohol Interactions

  • ACETAMINOPHEN - Concurrent use of ACETAMINOPHEN and ETHANOL may result in an increased risk of hepatotoxicity.
  • ACETOPHENAZINE - Concurrent use of ACETOPHENAZINE and ETHANOL may result in increased CNS depression and an increased risk of extrapyramidal reactions.
  • ACITRETIN - Concurrent use of ACITRETIN and ETHANOL may result in a prolonged risk of teratogenicity.
  • ALFENTANIL - Concurrent use of ALFENTANOL and ETHANOL may result in decreased therapeutic effects for Alfentanil.
  • ALPRAZOLAM - Concurrent use of ALPRAZOLAM and ETHANOL may result in increased sedation.
  • AMITRIPTYLINE - Concurrent use of AMITRIPTYLINE and ETHANOL may result in enhanced CNS depression and impairment of motor skills.
  • AMOBARBITAL - Concurrent use of AMOBARBITAL and ETHANOL may result in excessive CNS depression.
  • AMOXAPINE - Concurrent use of AMOXAPINE and ETHANOL may result in enhanced drowsiness and impairment of motor skills.
  • AMPRENAVIR - Concurrent use of AMPRENAVIR and ETHANOL may result in an increased risk of propylene glycol toxicity (seizures, tachycardia, lactic acidosis, renal toxicity, and hemolysis).
  • APROBARBITAL - Concurrent use of APROBARBITAL and ETHANOL may result in excessive CNS depression.
  • ASPIRIN - Concurrent use of ASPIRIN and ETHANOL may result in increased gastrointestinal blood loss.
  • ATORVASTATIN - Concurrent use of ATORVASTATIN and ETHANOL may cause liver problems.
  • BUPROPION - Concurrent use of BUPROPION and ETHANOL may result in an increased risk of seizures.
  • BUTABARBITAL - Concurrent use of BUTABARBITAL and ETHANOL may result in excessive CNS depression.
  • BUTALBITAL - Concurrent use of BUTALBITAL and ETHANOL may result in excessive CNS depression.
  • CALAMUS - Concurrent use of CALAMUS and ETHANOL may result in increased sedation.
  • CANNABIS - Concurrent use of CANNABIS and ETHANOL may result in increased intoxication.
  • CARVEDILOL PHOSPHATE - Concurrent use of CARVEDILOL, PHOSPHATE and ETHANOL may result in faster than normal rate of release of carvedilol phosphate.
  • CEFAMANDOLE - Concurrent use of CEFAMANDOLE and ETHANOL may result in disulfiram-like reactions.
  • CEFMENOXINE - Concurrent use of CEFMENOXINE and ETHANOL may result in disulfiram-like reactions.
  • CEFOPERAZONE - Concurrent use of CEFOPERAZONE and ETHANOL may result in disulfiram-like reactions.
  • CEFOTETAN - Concurrent use of CEFOTETAN and ETHANOL may result in disulfiram-like reactions.
  • CHAPARRAL - Concurrent use of CHAPARRAL and ETHANOL may result in elevated liver transaminases with or without concomitant hepatic damage.
  • CHLORAL HYDRATE - Concurrent use of CHLORAL HYDRATE and ETHANOL may result in increased sedation.
  • CHLORDIAZEPOXIDE - Concurrent use of CHLORDIAZEPOXIDE and ETHANOL may result in increased sedation.
  • CHLORPROMAZINE - Concurrent use of CHLORPROMAZINE and ETHANOL may result in increased sedation.
  • CHLORPROPAMIDE - Concurrent use of CHLORPROPAMIDE and ETHANOL may result in disulfiram-like reactions.
  • CIMETIDINE - Concurrent use of CIMETIDINE and ETHANOL may result in increased ethanol concentrations.
  • CISAPRIDE - Concurrent use of CISAPRIDE and ETHANOL may result in increased blood levels of ethanol.
  • CITALOPRAM - Concurrent use of CITALOPRAM and ETHANOL may result in potentiation of the cognitive and motor effects of alcohol.
  • CLOMIPRAMINE - Concurrent use of CLOMIPRAMINE and ETHANOL may result in enhanced drowsiness and impairment of motor skills.
  • CLORAZEPATE - Concurrent use of CLORAZEPATE and ETHANOL may result in increased sedation.
  • COCAINE - Concurrent use of COCAINE and ETHANOL may result in increased heart rate and blood pressure.
  • CODEINE - Concurrent use of CODEINE and ETHANOL may result in increased sedation.
  • COMFREY - Concurrent use of COMFREY and ETHANOL may result in elevated inner transaminases with or without concomitant hepatic damage.
  • CYCLOSERINE - Concurrent use of CYCLOSERINE and ETHANOL may result in an increased risk of seizures.
  • DEFLAZACORT - Concurrent use of DEFLAZACORT and ETHANOL may result bleeding & ulcers in the stomach.
  • DESIPRAMINE - Concurrent use of DESIPRAMINE and ETHANOL may result in enhanced drowsiness and impairment of motor skills.
  • DIAZEPAM - Concurrent use of DIAZEPAM and ETHANOL may result in increased sedation.
  • DIMETHINDENE - Concurrent use of DIMETHINDENE and ETHANOL may result in increased sedation.
  • DIPHENHYDRAMINE - Concurrent use of DIPHENHYDRAMINE and ETHANOL may result in increased sedation.
  • DISULFIRAM - Concurrent use of DISULFIRAM and ETHANOL may result in ethanol intolerance.
  • DOTHIEPIN - Concurrent use of ETHANOL and DOTHIEPIN may result in enhanced drowsiness and impairment of motor skills.
  • DOXEPIN - Concurrent use of DOXEPIN and ETHANOL may result in enhanced drowsiness and impairment of motor skills.
  • EMPAGLIFLOZIN - Concurrent use of EMPAGLIFLOZIN and ETHANOL may result hypoglycemia (low blood sugar) and hyperglycemia (high blood sugar) depending on how much and how often you drink.
  • ESCITALOPRAM - Concurrent use of ESCITALOPRAM and ETHANOL may result in potentiation of the cognitive and motor effects of alcohol.
  • ESZOPICLONE - Concurrent use of ESZOPICLONE and ETHANOL may result in impaired psychomotor functions and risk of increased sedation.
  • ETEROBARB - Concurrent use of ETEROBARB and ETHANOL may result in excessive CNS depression.
  • ETHOPROPAZINE - Concurrent use of ETHOPROPAZINE and ETHANOL may result in increased CNS depression and an increased risk of extrapyramidal reactions.
  • ERTUGLIFLOZIN - Concurrent use of ERTUGLIFLOZIN and ETHANOL may result low blood sugar and a high ketone level.
  • FLUNITRAZEPAM - Concurrent use of FLUNITRAZEPAM and ETHANOL may result in excessive sedation and psychomotor impairment.
  • FLUPHENAZINE - Concurrent use of FLUPHENAZINE and ETHANOL may result in increased CNS depression and an increased risk of extrapyramidal reactions.
  • FOMEPIZOLE - Concurrent use of FOMEPIZOLE and ETHANOL may result in the reduced elimination of both drugs.
  • FOSPHENYTOIN - Concurrent use of FOSPHENYTOIN and ETHANOL may result in decreased phenytoin serum concentrations, increased seizure potential, and additive CNS depressant effects.
  • FURAZOLIDONE - Concurrent use of FURAZOLIDONE and ETHANOL may result in disulfiram-like reactions.
  • GERMANDER - Concurrent use of GERMANDER and ETHANOL may result in elevated liver transaminases with or without concomitant hepatic damage.
  • GLIPIZIDE - Concurrent use of GLIPIZIDE and ETHANOL may result in prolonged hypoglycemia and disulfiram-like reactions.
  • GLICLAZIDE - Concurrent use of ETHANOL and GLICLAZIDE may result in prolonged hypoglycemia and disulfiram-like reactions.
  • GLUTETHIMIDE - Concurrent use of GLUTETHIMIDE and ETHANOL may result in increased sedation.
  • GLYBURIDE - Concurrent use of GLYBURIDE and ETHANOL may result in prolonged hypoglycemia and disulfiram-like reactions.
  • GOSSYPOL - Concurrent use of GOSSYPOL and ETHANOL may result in delayed effects of gossypol and/or increased toxic effects of ethanol.
  • GRISEOFULVIN - Concurrent use of GRISEOFULVIN and ETHANOL may result in disulfiram-like reactions.
  • GUAR GUM - Concurrent use of GUAR GUM and ETHANOL may result in increased intoxication effects of ethanol.
  • GUARANA - Concurrent use of GUARANA and ETHANOL may result in increased risk of ethanol intoxication.
  • HYDROCODONE - Concurrent use of HYDROCODONE and ETHANOL may result in increased sedation.
  • HYDROMORPHONE - Concurrent use of HYDROMORPHONE and ETHANOL may result in increased sedation.
  • IMIPRAMINE - Concurrent use of IMIPRAMINE and ETHANOL may result in enhanced drowsiness and impairment of motor skills.
  • INSULIN - Concurrent use of INSULIN and ETHANOL may result in increased hypoglycemia.
  • INSULIN LISPRO, HUMAN - Concurrent use of INSULIN LISPRO, HUMAN and ETHANOL and may result in increased hypoglycemia.
  • ISONIAZID - Concurrent use of ISONIAZID and ETHANOL may result in decreased isoniazid concentrations and disulfiram-like reactions.
  • ISOTRETINOIN - Concurrent use of ISOTRETINOIN and ETHANOL may result in disulfiram-like reactions.
  • KAVA - Concurrent use of KAVA and ETHANOL may result in increased CNS depression and/or increased risk of hepatotoxicity.
  • KETOCONAZOLE - Concurrent use of KETOCONAZOLE and ETHANOL may result in disulfiram-like reactions (flushing, vomiting, increased respiratory rate, and tachycardia).
  • LOFEPRAMINE - Concurrent use of LOFEPRAMINE and ETHANOL may result in enhanced drowsiness and impairment of motor skills.
  • LORAZEPAM - Concurrent use of LORAZEPAM and ETHANOL may result in increased sedation.
  • MEPERIDINE - Concurrent use of MEPERIDINE and ETHANOL may result in increased sedation.
  • MEPHOBARBITAL - Concurrent use of MEPHOBARBITAL and ETHANOL may result in excessive CNS depression.
  • MEPROBAMATE - Concurrent use of MEPROBAMATE and ETHANOL may result in increased sedation.
  • MESORIDAZINE - Concurrent use of MESORIDAZINE and ETHANOL may result in increased CNS depression and an increased risk of extrapyramidal reactions.
  • METFORMIN - Concurrent use of METFORMIN and ETHANOL may result in an increased risk of lactic acidosis.
  • METHADONE - Concurrent use of METHADONE and ETHANOL may result in increased sedation.
  • METHOCARBAMOL - Concurrent use of METHOCARBAMOL and ETHANOL may result nervous system side effects such as dizziness, drowsiness, and difficulty concentrating.
  • METHOHEXITAL - Concurrent use of METHOHEXITAL and ETHANOL may result in excessive CNS depression.
  • METHOTREXATE - Concurrent use of METHOTREXATE and ETHANOL may result in increased hepatotoxicity.
  • METHOTRIMEPRAZINE - Concurrent use of METHOTRIMEPRAZINE and ETHANOL may result in increased CNS depression and an increased risk of extrapyramidal reactions.
  • METRONIDAZOLE - Concurrent use of METRONIDAZOLE and ETHANOL may result in disulfiram-like reactions (flushing, increased respiratory rate, tachycardia) or sudden death.
  • MIRTAZAPINE - Concurrent use of MIRTAZAPINE and ETHANOL may result in psychomotor impairment.
  • MORPHINE - Concurrent use of MORPHINE and ETHANOL may result in increased risk of respiratory depression, hypotension, profound sedation, or coma.
  • MORPHINE SULFATE LIPOSOME - Concurrent use of MORPHINE SULFATE LIPOSOME and ETHANOL may result in increased risk of respiratory depression, hypotension, profound sedation, or coma.
  • MOXALACTAM - Concurrent use of ETHANOL and MOXALACTAM may result in disulfiram-like reactions.
  • NEFAZODONE - Concurrent use of NEFAZODONE and ETHANOL may result in an increased risk of CNS side effects.
  • NIACIN - Concurrent use of NIACIN and ETHANOL may result in increased side effects of flushing and pruritus.
  • NILUTAMIDE - Concurrent use of NILUTAMIDE and ETHANOL may result in an increased risk of ethanol intolerance (facial flushing, malaise, and hypotension).
  • NITROGLYCERIN - Concurrent use of NITROGLYCERIN and ETHANOL may result in hypotension.
  • NORTRIPTYLINE - Concurrent use of NORTRIPTYLINE and ETHANOL may result in enhanced drowsiness and impairment of motor skills.
  • OLANZAPINE - Concurrent use of OLANZAPINE and ETHANOL may result in excessive CNS depression.
  • OXYCODONE - Concurrent use of OXYCODONE and ETHANOL may result in increased sedation.
  • OXYMORPHONE - Concurrent use of OXYMORPHONE and ETHANOL may result in increased oxymorphone plasma levels (extended-release formulation) and additive CNS/ respiratory depression.
  • PARALDEHYDE - Concurrent use of PARALDEHYDE and ETHANOL may result in metabolic acidosis.
  • PAROXETINE - Concurrent use of PAROXETINE and ETHANOL may increase the risk of mental and motor-skill impairment.
  • PENNYROYAL - Concurrent use of PENNYROYAL and ETHANOL may result in elevated liver transaminases with or without concomitant hepatic damage.
  • PENTAZOCINE - Concurrent use of PENTAZOCINE and ETHANOL may result in increased sedation.
  • PERPHENAZINE - Concurrent use of PERPHENAZINE and ETHANOL may result in increased CNS depression and an increased risk of extrapyramidal reactions.
  • PHENELZINE - Concurrent use of PHENELZINE and ETHANOL may result in hypertension urgency or emergency.
  • PHENOBARBITAL - Concurrent use of PHENOBARBITAL and ETHANOL may result in excessive CNS depression.
  • PHENYTOIN - Concurrent use of PHENYTOIN and ETHANOL may result in decreased phenytoin serum concentrations, increased seizure potential, and additive CNS depressant effects.
  • PIPOTIAZINE - Concurrent use of PIPOTIAZINE and ETHANOL may result in increased CNS depression and an increased risk of extrapyramidal reactions.
  • PREGABALIN (LYRICA) - Concurrent use of PREGABALIN and ETHANOL increase the nervous system side effects of such as dizziness, drowsiness, and difficulty concentrating.
  • PRIMIDONE - Concurrent use of PRIMIDONE and ETHANOL may result in excessive CNS depression.
  • PROCARBAZINE - Concurrent use of PROCARBAZINE and ETHANOL may result in disulfiram-like reactions and increased sedation.
  • PROCHLORPERAZINE - Concurrent use of PROCHLORPERAZINE and ETHANOL may result in increased CNS depression and an increased risk of extrapyramidal reactions.
  • PROMAZINE - Concurrent use of PROMAZINE and ETHANOL may result in increased CNS depression and an increased risk of extrapyramidal reactions.
  • PROPIOMAZINE - Concurrent use of PROPIOMAZINE and ETHANOL may result in increased CNS depression and an increased risk of extrapyramidal reactions.
  • PROTRIPTYLINE - Concurrent use of PROTRIPTYLINE and ETHANOL may result in enhanced drowsiness and impairment of motor skills.
  • QUETIAPINE - Concurrent use of QUETIAPINE and ETHANOL may result in potentiation of the cognitive and motor effects of alcohol.
  • REMDESIVIR - Concurrent use of REMDESIVIR and ETHANOL may result liver problems.
  • ROSUVASTATIN - Concurrent use of ROSUVASTATIN and ETHANOL may cause liver problems.
  • SECOBARBITAL - Concurrent use of SECOBARBITAL and ETHANOL may result in excessive CNS depression.
  • SERTRALINE - Concurrent use of SERTRALINE and ETHANOL may increase the risk of mental and motor-skill impairment.
  • SULFAMETHOXAZOLE - Concurrent use of SULFAMETHOXAZOLE and ETHANOL may result in disulfiram-like reactions (flushing, sweating, palpitations, and drowsiness).
  • TACROLIMUS - Concurrent use of TACROLIMUS and ETHANOL may result in alcohol-related flushing and rash.
  • TADALAFIL - Concurrent use of TADALAFIL and ETHANOL may result in an increased risk of hypotension and orthostatic signs and symptoms.
  • TEMAZEPAM - Concurrent use of TEMAZEPAM and ETHANOL may result in impaired psychomotor functions.
  • THIETHYLPERAZINE - Concurrent use of THIETHYLPERAZINE and ETHANOL may result in increased CNS depression and an increased risk of extrapyramidal reactions.
  • THIEOPENTAL - Concurrent use of THIEOPENTAL and ETHANOL may result in excessive CNS depression.
  • THIORIDAZINE - Concurrent use of THIORIDAZINE and ETHANOL may result in increased CNS depression and an increased risk of extrapyramidal reactions.
  • TIZANIDINE - Concurrent use of TIZANIDINE and ETHANOL may increase the risk of tizanidine adverse effects (excessive CNS depression).
  • TOLAZAMIDE - Concurrent use of TOLAZAMIDE and ETHANOL may result in prolonged hypoglycemia and disulfiram-like reactions.
  • TOLAZOLINE - Concurrent use of TOLAZOLINE and ETHANOL may result in disulfiram-like reactions.
  • TOLBUTAMIDE - Concurrent use of TOLBUTAMIDE and ETHANOL may result in prolonged hypoglycemia and disulfiram-like reactions.
  • TRAMADOL - Concurrent use of TRAMADOL and ETHANOL may increase the risk of excessive CNS depression.
  • TRANYLCYPROMINE - Concurrent use of TRANYLCYPROMINE and ETHANOL may result in hypertensive urgency or emergency.
  • TRIAZOLAM - Concurrent use of TRIAZOLAM and ETHANOL may result in increased sedation.
  • TRIFLUPERAZINE - Concurrent use of TRIFLUPERAZINE and ETHANOL may result in increased CNS depression and an increased risk of extrapyramidal reactions.
  • TRIFLUPROMAZINE - Concurrent use of TRIFLUPROMAZINE and ETHANOL may result in increased CNS depression and an increased risk of extrapyramidal reactions.
  • TRIMETHOPRIM - Concurrent use of ETHANOL and COTRIMOXAZOLE may result in disulfiram-like reactions.
  • TRIMIPRAMINE - Concurrent use of TRIMIPRAMINE and ETHANOL may result in enhanced drowsiness and impairment of motor skills.
  • VALERIAN - Concurrent use of VALERIAN and ETHANOL may result in increased sedation.
  • VENLAFAXINE - Concurrent use of VENLAFAXINE and ETHANOL may result in an increased risk of CNS effects.
  • VERAPAMIL - Concurrent use of VERAPAMIL and ETHANOL may result in enhanced ethanol intoxication (impaired psychomotor functioning).
  • WARFARIN - Concurrent use of WARFARIN and ETHANOL may result in increased or decreased international normalized ratio (INR) or prothrombin time.
  • YOHIMBINE - Concurrent use of YOHIMBINE and ETHANOL may result in increased ethanol intoxication and increased anxiety and blood pressure.
  • ZALEPLON - Concurrent use of ZALEPLON and ETHANOL may result in impaired psychomotor functions.
  • ZOLPIDEM - Concurrent use of ZOLPIDEM and ETHANOL may result in increased sedation.


Read also:

Post a Comment

Post a Comment